This page shows the latest eltrombopag news and features for those working in and with pharma, biotech and healthcare.
For rare blood disorder drug Promacta (eltrombopag), the status was awarded for its use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic anaemia (SAA) as
new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP).
The Swiss company announced this morning that platelet-boosting drug Revolade (eltrombopag) has become the first approved drug in the EU for adults with the rare blood disorder severe aplastic anaemia
The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined
Promacta (eltrombopag) will be a treatment option for child patients who have had an insufficient response to corticosteroids, immunoglobins or splenectomy following its approval for adults in 2008. ... ITP who have either an insufficient response to or
Over the last year, the EMA has recommended marketing authorisations for four new medicines for the treatment of HCV, including GSK's Revolade (eltrombopag) and Janssen's Olysio (simeprevir).
More from news
Approximately 6 fully matching, plus 19 partially matching documents found.
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...